The opioid agonist morphine decreases the dyskinetic response to dopaminergic agents in parkinsonian monkeys

Neurobiology of Disease

Volumn 16, Issue 1, 2004, Pages 246-253

  Samadi, Pershia ^b   Grégoire, Laurent ^b   Bédard, Paul J ^a  

^a LAVAL UNIVERSITY   (Canada)

^b NONE

Author keywords

Basal ganglia; Dopamine; Dyskinesias; Opioids; Parkinson

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MORPHINE; OPIATE AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; DYSKINESIA; FEMALE; MONKEY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; SYNAPTIC TRANSMISSION;

ANALGESICS, OPIOID; ANIMALS; DOPAMINE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIA, DRUG-INDUCED; FEMALE; MACACA FASCICULARIS; MORPHINE; PARKINSONIAN DISORDERS; RECEPTORS, OPIOID;

EID: 2342576336     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2004.02.002     Document Type: Article

References (53)

1. Bédard P.J., Blanchet P.J., Lévesque D., Soghomonian J.J., Grondin R., Morissette M., Goulet M., Calon F., Falardeau P., Gomez-Mancilla B., Doucet J.P., Robertson G.S., DiPaolo T. Pathophysiology of L-dopa-induced dyskinesias. Mov. Disord. 14(Suppl. 1):1999;4-8
2. Berg D., Becker G., Reiners K. Reduction of dyskinesia and induction of akinesia induced by morphine in two parkinsonian patients with severe sciatica. J. Neural Transm. 106:1999;725-728
3. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine monkeys. Neurobiol. Dis. 8:2001;343-350
4. Blanchet P.J., Allard P., Grégoire L., Tardif F., Bédard P.J. Risk factors for peak dose dyskinesia in 100 levodopa-treated parkinsonian patients. Can. J. Neurol. Sci. 23:1996;189-193
5. Brotchie J.M. Adjuncts to dopamine replacement: a pragmatic approach to reducing the problem of dyskinesia in Parkinson's disease. Mov. Disord. 13:1998;871-876
6. Brotchie J.M., Henry B., Hille C.J., Crossman A.R. Opioid peptide precursor expression in animal models of dystonia secondary to dopamine-replacement therapy in Parkinson's disease. Adv. Neurol. 78:1998;41-52
7. Calon F., Birdi S., Rajput A.H., Hornykiewicz O., Bédard P.J., Di Paolo T. Increase of preproenkephalin mRNA levels in the putamen of Parkinson disease patients with levodopa-induced dyskinesias. J. Neuropathol. Exp. Neurol. 61:2002;186-196
8. Campbell K., Bjorklund A. Prefrontal corticostriatal afferents maintain increased enkephalin gene expression in the dopamine-denervated rat striatum. Eur. J. Neurosci. 6:1994;1371-1383
9. Comb M., Seeburg P.H., Adelman J., Eiden L., Herbert E. Primary structure of the human Met- and Leu-enkephalin precursor and its mRNA. Nature. 295:1982;663-666
10. Dhawan B.N., Cesselin F., Raghubir R., Reisine T., Bradley P.B., Portoghese P.S., Hamon M. International Union of Pharmacology. XII. Classification of opioid receptors. Pharmacol. Rev. 48:1996;567-592
11. Duty S., Henry B., Crossman A.R., Brotchie J.M. Topographical organization of opioid peptide precursor gene expression following repeated apomorphine treatment in the 6-hydroxydopamine-lesioned rat. Exp. Neurol. 150:1998;223-234
12. Fuxe K., Ferre S., Zoli M., Agnati L.F. Integrated events in central dopamine transmission as analyzed at multiple levels. Evidence for intramembrane adenosine A2A/dopamine D2 and adenosine A1/dopamine D1 receptor interactions in the basal ganglia. Brain Res. Brain Res. Rev. 26:1998;258-273
13. Gerfen C.R., Engber T.M., Mahan L.C., Susel Z., Chase T.N., Monsma F.J. Jr., Sibley D.R. D1 and D2 dopamine receptor-regulated gene expression of striatonigral and striatopallidal neurons. Science. 250:1990;1429-1432
14. Gerfen C.R., McGinty J.F., Young W.S. III Dopamine differentially regulates dynorphin, substance P, and enkephalin expression in striatal neurons: in situ hybridization histochemical analysis. J. Neurosci. 11:1991;1016-1031
15. Greengard P. The neurobiology of slow synaptic transmission. Science. 294:2001;1024-1030
16. Hadj Tahar A., Ekesbo A., Grégoire L., Bangassoro E., Svensson K.A., Tedroff J., Bédard P.J. Effects of acute and repeated treatment with a novel dopamine D2 receptor ligand on L-DOPA-induced dyskinesias in MPTP monkeys. Eur. J. Pharmacol. 412:2001;247-254
17. Hadj Tahar A., Grondin R., Grégoire L., Calon F., Di Paolo T., Bédard P.J. New insights in Parkinson's disease therapy: can levodopa induced dyskinesia ever be manageable. Gordin A., Kaakkola S., Teravainen H. Parkinsons' Disease: Advances in Neurology. 2003;51-64 Lippincott Williams and Wilkins, Philadelphia
18. Hajji M.D., Salin P., Kerkerian-le Goff L. Chronic dizocilpine maleate (MK-801) treatment suppresses the effects of nigrostriatal dopamine deafferentation on enkephalin but not on substance P expression in the rat striatum. Eur. J. Neurosci. 8:1996;917-926
19. Halimi G., Devaux C., Clot-Faybesse O., Sampol J., Legof L., Rochat H., Guieu R. Modulation of adenosine concentration by opioid receptor agonists in rat striatum. Eur. J. Pharmacol. 398:2000;217-224
20. Henry B., Brotchie J.M. Potential of opioid antagonists in the treatment of levodopa-induced dyskinesias in Parkinson's disease. Drugs Aging. 9:1996;149-158
21. Henry B., Fox S.H., Crossman A.R., Brotchie J.M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Exp. Neurol. 171:2001;139-146
22. Jiang Z.G., North R.A. Pre- and postsynaptic inhibition by opioids in rat striatum. J. Neurosci. 12:1992;356-361
23. Kieffer B.L. Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell. Mol. Neurobiol. 15:1995;615-635
24. Li S.J., Jiang H.K., Stachowiak M.S., Hudson P.M., Owyang V., Nanry K., Tilson H.A., Hong J.S. Influence of nigrostriatal dopaminergic tone on the biosynthesis of dynorphin and enkephalin in rat striatum. Brain Res. Mol. Brain Res. 8:1990;219-225
25. Lindskog M., Svenningsson P., Fredholm B., Greengard P., Fisone G. Mu- and delta-opioid receptor agonists inhibit DARPP-32 phosphorylation in distinct populations of striatal projection neurons. Eur. J. Neurosci. 11:1999;2182-2186
26. Manson A.J., Katzenschlager R., Hobart J., Lees A.J. High dose naltrexone for dyskinesias induced by levodopa. J. Neurol. Neurosurg. Psychiatry. 70:2001;554-556
27. Mansour A., Khachaturian H., Lewis M.E., Akil H., Watson S.J. Autoradiographic differentiation of mu, delta, and kappa opioid receptors in the rat forebrain and midbrain. J. Neurosci. 7:1987;2445-2464
28. Marsden C.D. Problems with long-term levodopa therapy for Parkinson's disease. Clin. Neuropharmacol. 17(Suppl. 2):1994;S32-S44
29. Meissner W., Dovero S., Bioulac B., Gross C.E., Bezard E. Compensatory regulation of striatal neuropeptide gene expression occurs before changes in metabolic activity of basal ganglia nuclei. Neurobiol. Dis. 13:2003;46-54
30. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bédard P.J., Di Paolo T. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with L-DOPA therapy. Brain Res. Mol. Brain Res. 49:1997;55-62
31. Morissette M., Grondin R., Goulet M., Bédard P.J., Di Paolo T. Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists. J. Neurochem. 72:1999;682-692
32. Nash J.E., Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: implications for the treatment of Parkinson's disease. J. Neurosci. 20:2000;7782-7789
33. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: problems with the current model. Ann. Neurol. 47:2000;S22-S32
34. Oh J.D., Del Dotto P., Chase T.N. Protein kinase A inhibitor attenuates levodopa-induced motor response alterations in the hemi-parkinsonian rat. Neurosci. Lett. 228:1997;5-8
35. Parent A., Sato F., Wu Y., Gauthier J., Lévesque M., Parent M. Organization of the basal ganglia: the importance of axonal collateralization. Trends Neurosci. 23:2000;S20-S27
36. Peckys D., Landwehrmeyer G.B. Expression of mu, kappa, and delta opioid receptor messenger RNA in the human CNS: a 33P in situ hybridization study. Neuroscience. 88:1999;1093-1135
37. Picconi B., Centonze D., Hakansson K., Bernardi G., Greengard P., Fisone G., Cenci M.A., Calabresi P. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat. Neurosci. 6:2003;501-506
38. Pollack A.E. Anatomy, physiology, and pharmacology of the basal ganglia. Neurol. Clin. 19:2001;523-534
39. Quik M., Police S., Langston J.W., Di Monte D.A. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience. 113:2002;213-220
40. Rascol O., Fabre N., Blin O., Poulik J., Sabatini U., Senard J.M., Ane M., Montastruc J.L., Rascol A. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease. Mov. Disord. 9:1994;437-440
41. Samadi P., Grégoire L., Bédard P.J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: interaction between dopamine and opioid systems. Neuropharmacology. 45:2003;954-963
42. Schiffmann S.N., Vanderhaeghen J.J. Adenosine A2 receptors regulate the gene expression of striatopallidal and striatonigral neurons. J. Neurosci. 13:1993;1080-1087
43. Schneider J.S., Decamp E., Wade T. Striatal preproenkephalin gene expression is upregulated in acute but not chronic parkinsonian monkeys: implications for the contribution of the indirect striatopallidal circuit to parkinsonian symptomatology. J. Neurosci. 19:1999;6643-6649
44. Schroeder J.A., Schneider J.S. Striatal enkephalin gene expression does not reflect parkinsonian signs. NeuroReport. 11:2000;1799-1802
45. Smith A.D., Bolam J.P. The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones. Trends Neurosci. 13:1990;259-265
46. Starr M.S. Glutamate/dopamine D1/D2 balance in the basal ganglia and its relevance to Parkinson's disease. Synapse. 19:1995;264-293
47. Svenningsson P., Lindskog M., Rognoni F., Fredholm B.B., Greengard P., Fisone G. Activation of adenosine A2A and dopamine D1 receptors stimulates cyclic AMP-dependent phosphorylation of DARPP-32 in distinct populations of striatal projection neurons. Neuroscience. 84:1998;223-228
48. Voorn P., Docter G.J., Jongen-Relo A.L., Jonker A.J. Rostrocaudal subregional differences in the response of enkephalin, dynorphin and substance P synthesis in rat nucleus accumbens to dopamine depletion. Eur. J. Neurosci. 6:1994;486-496
49. Wang H., Pickel V.M. Preferential cytoplasmic localization of delta-opioid receptors in rat striatal patches: comparison with plasmalemmal mu-opioid receptors. J. Neurosci. 21:2001;3242-3250
50. Wang H., Gracy K.N., Pickel V.M. Mu-opioid and NMDA-type glutamate receptors are often colocalized in spiny neurons within patches of the caudate-putamen nucleus. J. Comp. Neurol. 412:1999;132-146
51. Williams J.T., Christie M.J., Manzoni O. Cellular and synaptic adaptations mediating opioid dependence. Physiol. Rev. 81:2001;299-343
52. Xie C.W., Lewis D.V. Involvement of cAMP-dependent protein kinase in mu-opioid modulation of NMDA-mediated synaptic currents. J. Neurophysiol. 78:1997;759-766
53. Zeng B.Y., Jolkkonen J., Jenner P., Marsden C.D. Chronic L-DOPA treatment differentially regulates gene expression of glutamate decarboxylase, preproenkephalin and preprotachykinin in the striatum of 6-hydroxydopamine- lesioned rat. Neuroscience. 66:1995;19-28